By The Texas Construction News staff writer
HOUSTON — Bristol Myers Squibb has selected Generation Park in Houston as the site for a new multi-modal manufacturing campus. Announced on Aug. 10, the project represents a $2.3 billion investment in domestic manufacturing capabilities.
The 600,000-sq. Ft. structure is designed to manufacture multiple types of medicines, including small molecules, biologics, and antibody-drug conjugates. The modular design of the campus will allow the pharmaceutical company to rapidly configure capacity to meet pipeline demands, ultimately creating nearly 500 skilled jobs.
While the specific architect, engineering firm, and general contractor have not yet been publicly disclosed, the sheer scale of the development will create a significant pipeline of work for local trades. According to corporate announcements, the project is expected to generate approximately 2,000 construction and indirect jobs during the build phase, which is slated to run from 2027 through 2030.
The campus’s modular architecture is explicitly built for adaptability. It incorporates configuration flexibility that anticipates future advances in digital integration and automation, ensuring the facility can safely scale its capabilities as commercial requirements evolve.
The site is located within Generation Park, a 4,300-acre master-planned commercial district near Lake Houston that is quickly establishing itself as a hub for life sciences and advanced manufacturing. The new campus joins a previously announced $6.5 billion Eli Lilly manufacturing plant, further solidifying the area’s density of domestic pharmaceutical production.
To attract the development, the State of Texas extended a $4.89 million Texas Enterprise Fund grant to the company. Gov. Greg Abbott’s office also noted the expansion is a qualified project under the state’s newly created Jobs, Energy, Technology, and Innovation (JETI) program, which supports capital-intensive economic development projects.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” Christopher Boerner, Board Chair and CEO of Bristol Myers Squibb, stated following the announcement. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
